Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
Ximelagatran reduced composite morbidity/mortality versus warfarin in AF patients; confirms consistent benefit irrespective of HF markers.
Cleland et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: